Mersana Therapeutics (NASDAQ: MRSN) reported Q1 EPS of ($0.52), $0.09 worse than the analyst estimate of ($0.43). Revenue for the quarter came in at $7.8 million versus the consensus estimate of $15.4 million.

For earnings history and earnings-related data on Mersana Therapeutics (MRSN) click here.